RZLT 10 Year Annualized Return and Average Annual Return

The RZLT 10 year annualized return is -23.70% with dividends reinvested through 05/08/2026. Investors often use annualized return to compare long-term performance because it shows the average yearly compounded return over a full period rather than just the headline total gain.

This page shows RZLT average annual return, total return, start and end dates, and the growth of a hypothetical $10,000 investment with dividends reinvested.

Quick links: Annualized Return Table  |  Performance Chart  |  FAQ
RZLT Average Annual Return Chart 10 Years
Growth of $10,000.00
Without Dividends Reinvested Into RZLT

Also see:
• RZLT stock yearly return 2016
• RZLT stock yearly return 2017
• RZLT stock yearly return 2018
• RZLT stock yearly return 2019
• RZLT stock yearly return 2020
• RZLT stock yearly return 2021
• RZLT stock yearly return 2022
• RZLT stock yearly return 2023
• RZLT stock yearly return 2024
• RZLT stock yearly return 2025
• RZLT YTD return
Average Annual Return Benchmarks
Compare RZLT average annual return versus benchmarks:

S&P Average Annual Return
Dow Average Annual Return
Nasdaq 100 Average Annual Return
Russell 2000 Average Annual Return
Gold Average Annual Return
10 Year Treasury Average Annual Return
RZLT Share Performance
RZLT Average Annual Return Table 10 Years
Start date: 05/10/2016
End date: 05/08/2026
Start price/share: $48.00
End price/share: $3.21
Dividends collected/share: $0.00
Total return: -93.31%
RZLT Average Annual Return: -23.70%
Starting investment: $10,000.00
Ending investment: $668.72
Years: 10.00


RZLT average annual return is presented with the assumption of reinvestments of any dividends on ex-date.
About Rezolute Inc
Rezolute, Inc. is a late-stage rare disease company, which is focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism (HI). Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. The RZLT average annual return 10 years is shown above.

The Average Annual Return on the RZLT average annual return 10 years page and across the coverage universe of our site, is a measure of the annualized return over the past ten years (or specified start date) for a given investment (up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window to capture long-term trends.

Thus, researching Average Annual Returns is good practice for investors — whether RZLT average annual return 10 years or other benchmarks/peers — and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors by performing the RZLT average annual return calculation with any dividends reinvested as applicable (on ex-dates).
RZLT Current Stock Quote
Quotes delayed 20 minutes

Email EnvelopeFree RZLT Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
Featured Slideshows
10 Most Oversold Stocks in the S&P
10 Most Overbought Stocks in the S&P
10 ETFs With Stocks That Insiders Are Buying
10 ETFs With Most Upside To Analyst Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Energy Stocks You Can Buy Cheaper Than Insiders Did
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active Call & Put Options of the S&P 500 Components
Video: Don't Forget Dividends in Average Annual Return!
Video: Don't Forget Dividends in Average Annual Return!
Average Annual Return Peers
Rezolute (RZLT) is categorized under the Healthcare sector; to help you further research average annual return performance across stocks, below are some other companies in the same sector:

SABS Average Annual Return
SANA Average Annual Return
SBFM Average Annual Return
SCYX Average Annual Return
SDGR Average Annual Return
SEER Average Annual Return
SEM Average Annual Return
SENS Average Annual Return
SERA Average Annual Return
SGHT Average Annual Return
More Healthcare companies »
What has the average annual return been for RZLT over the past ten years?
✔️Accepted answer: The ten year RZLT average annual return has been -23.70%.

What start date was used in your RZLT average annual return calculation?
✔️Accepted answer: The start date was 05/10/2016.

What end date was used in your RZLT average annual return calculation?
✔️Accepted answer: The end date was 05/08/2026.

If I had invested $10,000 into RZLT ten years ago, how much would I have today?
✔️Accepted answer: Today, as of 05/08/2026, you would have $668.72.

What does that work out to on a total return basis?
✔️Accepted answer: The RZLT ten year total return ending 05/08/2026 works out to -93.31%.


Also see:
• RZLT stock yearly return 2016
• RZLT stock yearly return 2017
• RZLT stock yearly return 2018
• RZLT stock yearly return 2019
• RZLT stock yearly return 2020
• RZLT stock yearly return 2021
• RZLT stock yearly return 2022
• RZLT stock yearly return 2023
• RZLT stock yearly return 2024
• RZLT stock yearly return 2025
• RZLT YTD return
 

RZLT 10 Year Annualized Return & Average Annual Return | www.AverageAnnualReturn.com | Copyright © 2021 - 2026, All Rights Reserved

Nothing in AverageAnnualReturn.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.